Gene therapy is a medical approach that aims to treat, prevent or potentially cure disease by changing genetic material or genetic activity within a patients cells. The concept includes several strategies, such as adding a functional copy of a gene, replacing or correcting a defective sequence, disrupting a harmful gene, modifying gene expression, or introducing genetic instructions that cause cells to produce a therapeutic molecule.
Gene therapy is particularly relevant to diseases in which genetic abnormalities play a significant role, but genetic approaches can also be investigated for acquired diseases such as cancer. The central distinction is therapeutic purpose: gene therapy is genetic intervention undertaken to achieve a medical benefit. It is therefore different from genetic modification as a general technological category, because genetic modification can be used for research, agriculture, industrial biotechnology or other purposes that are not medical treatment.
Gene therapy can be divided into several broad categories according to what is changed and where the intervention occurs. Gene addition introduces genetic information intended to provide a functional product without necessarily replacing the original defective gene. Gene replacement or editing attempts to alter the endogenous genetic sequence itself. Gene silencing can reduce production of a harmful protein, while gene regulation approaches can increase or decrease expression of existing genes.
Some therapies introduce genes that help immune cells recognise cancer cells or otherwise change cellular behaviour. Another distinction concerns whether cells are treated inside or outside the body. In ex vivo therapy, cells are collected from the patient, genetically modified in a controlled laboratory environment and then returned. In vivo therapy delivers the genetic treatment directly to tissues within the patient. These approaches require different delivery systems, manufacturing procedures and monitoring strategies.
Delivery is one of the central technical problems in gene therapy because therapeutic genetic material must reach the correct cells and remain functional for an appropriate period. Viral vectors are widely studied because viruses have naturally evolved mechanisms for entering cells and delivering genetic material. Different viral vector types have different tissue preferences, payload capacities, persistence characteristics and immune properties.
Adeno associated virus vectors have been investigated extensively for delivering genes to particular tissues, while lentiviral vectors are commonly used in certain ex vivo cellular therapies because they can integrate genetic material into the genome of treated cells. Non viral systems include lipid nanoparticles and other engineered delivery technologies. The choice of delivery method depends on factors including target tissue, size of the genetic payload, desired duration of expression, route of administration and immune considerations. No single vector is optimal for every disease or tissue.
Some gene therapies seek long lasting changes, while others are designed to produce temporary effects. If therapeutic DNA remains episomal rather than integrating into the chromosomes, its persistence can vary according to the cell type and whether cells divide. Integrating vectors can provide stable inheritance of the introduced sequence within treated cell lineages, but integration can also create risks if the insertion affects important genes or regulatory regions.
Genome editing can create permanent changes at specific DNA locations and may therefore provide a different therapeutic strategy from transient delivery of genetic instructions. In rapidly dividing tissues, maintaining therapeutic genetic material can be particularly challenging. The desired duration of expression is therefore an important design consideration. A therapy intended to correct a lifelong inherited disorder may require durable genetic effects, whereas other conditions may be treated using temporary modulation of gene activity.
Gene therapy has developed from experimental concepts into clinically established approaches for some diseases, although its effectiveness varies greatly between conditions. Early clinical research encountered substantial technical and safety difficulties, including inefficient delivery and immune reactions. Improvements in vector design, cell culture, genetic engineering and patient selection have enabled some therapies to achieve meaningful clinical effects. Certain inherited disorders can be treated by supplying a functional gene, while genetically modified immune cells have been developed for particular cancers.
Gene therapy research also encompasses diseases where the target is not a single defective gene, because cells can be engineered to perform therapeutic functions. Clinical development requires evidence concerning efficacy, manufacturing quality, dosing, durability and safety, followed by regulatory assessment. The existence of an approved gene therapy for one disease does not mean that the same strategy will work for unrelated conditions.
Gene therapy has important risks and limitations. Immune responses may occur against viral vectors, introduced proteins or genetically modified cells. Some delivery systems have limited capacity for large genes. Treatment may reach only a fraction of the relevant cells, and the resulting level of gene expression may be insufficient or excessive. Genome editing can produce unintended alterations, while integrating vectors can present insertion related risks.
Some therapies are difficult to manufacture at large scale because patients may require individually processed cells or highly specialised biological products. Long term monitoring may be necessary because some genetic interventions can persist for years or produce permanent genomic changes. There are also practical issues involving treatment access, cost, specialised clinical infrastructure and patient eligibility. Gene therapy therefore represents a powerful therapeutic class but not a universal solution to genetic disease.
Somatic gene therapy and germline genetic modification must be distinguished carefully. Somatic gene therapy modifies cells in an individual patient and is intended to affect that person rather than deliberately introduce a heritable genetic change into future generations. Germline modification targets reproductive cells or early embryos and can potentially transmit genetic alterations to descendants. Germline interventions have much broader biological and ethical implications and are treated differently from established somatic gene therapy.
Gene therapy should also be distinguished from conventional drug therapy. A conventional drug generally acts through a chemical or biological molecule administered to the patient, whereas gene therapy introduces, alters or regulates genetic information or genetically modified cells. Some modern therapies blur traditional categories because nucleic acid medicines, RNA therapies and cell therapies can all manipulate biological information without necessarily being classified as gene therapy in every regulatory context.
The fundamental aim of gene therapy is to use genetic information as part of a therapeutic mechanism. This can involve restoring a missing biological function, reducing a harmful function, altering cellular behaviour or enabling a patients own cells to perform a therapeutic task. Its development depends on genetics, molecular biology, virology, immunology, cell biology, medicine and biotechnology working together.
The most important conceptual point is that gene therapy is defined by therapeutic intent and genetic mechanism rather than by one particular technology. Viral vectors, non viral delivery systems, genome editing, gene addition, gene silencing and engineered cell therapies can all belong to the broader field. As genetic understanding and delivery technologies improve, gene therapy continues to expand, but each proposed treatment must be evaluated according to its particular molecular target, delivery method, biological effect, risks and clinical evidence.
